DE69917400D1 - 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer - Google Patents

4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer

Info

Publication number
DE69917400D1
DE69917400D1 DE69917400T DE69917400T DE69917400D1 DE 69917400 D1 DE69917400 D1 DE 69917400D1 DE 69917400 T DE69917400 T DE 69917400T DE 69917400 T DE69917400 T DE 69917400T DE 69917400 D1 DE69917400 D1 DE 69917400D1
Authority
DE
Germany
Prior art keywords
cholesterol
inhibitors
levels
ldl
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69917400T
Other languages
English (en)
Other versions
DE69917400T2 (de
Inventor
Stephen Wayne Goldstein
Michael Raymond Makowski
Roger Benjamin Ruggeri
Ronald Thure Wester
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE69917400D1 publication Critical patent/DE69917400D1/de
Application granted granted Critical
Publication of DE69917400T2 publication Critical patent/DE69917400T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69917400T 1998-09-17 1999-09-14 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer Expired - Fee Related DE69917400T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10072998P 1998-09-17 1998-09-17
US100729P 1998-09-17

Publications (2)

Publication Number Publication Date
DE69917400D1 true DE69917400D1 (de) 2004-06-24
DE69917400T2 DE69917400T2 (de) 2005-05-19

Family

ID=22281233

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69917400T Expired - Fee Related DE69917400T2 (de) 1998-09-17 1999-09-14 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer

Country Status (10)

Country Link
US (2) US6140342A (de)
EP (1) EP0987251B1 (de)
JP (1) JP3626641B2 (de)
AT (1) ATE267172T1 (de)
BR (1) BR9904141A (de)
CA (1) CA2282183C (de)
DE (1) DE69917400T2 (de)
DK (1) DK0987251T3 (de)
ES (1) ES2220013T3 (de)
PT (1) PT987251E (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
DE10035352A1 (de) * 2000-07-20 2002-01-31 Zlb Bioplasma Ag Bern Verfahren zur Behandlung von instabiler Angina pectoris
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AU2001286243A1 (en) * 2000-09-14 2002-03-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
DE10063486A1 (de) * 2000-12-20 2002-07-04 Bayer Ag Dichlorpyridylmethylamide
EE200400024A (et) * 2001-06-21 2004-06-15 Pfizer Products Inc. Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE60238193D1 (de) 2001-06-22 2010-12-16 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
EP1269994A3 (de) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
BR0315041A (pt) * 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556356B1 (de) * 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydrochinolin-derivate als crth2 antagonisten
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1435356A1 (de) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Chinolinderivate als CRTH2-Antagonisten
CA2519458A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
NZ542852A (en) 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
RU2330682C2 (ru) * 2003-09-26 2008-08-10 Джапан Тобакко Инк. Способ ингибирования продуцирования остаточных липопротеинов
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
US7880006B2 (en) * 2004-08-04 2011-02-01 Meiji Seika Kaisha, Ltd. Quinoline derivatives and insecticide comprising thereof as active ingredient
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
MX2007010215A (es) 2005-02-24 2007-11-07 Millennium Pharm Inc Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias.
US20060270675A1 (en) * 2005-03-10 2006-11-30 Groneberg Robert D Inhibitors of cholesterol ester transfer protein
WO2006098394A1 (ja) * 2005-03-14 2006-09-21 Japan Tobacco Inc. 脂質吸収抑制方法および脂質吸収抑制剤
US7678818B2 (en) * 2006-02-07 2010-03-16 Hoffmann-La Roche Inc. Anthranilamide and 2-amino-heteroarene-carboxamide compounds
ES2449571T3 (es) * 2006-07-20 2014-03-20 Novartis Ag Derivados de amino-piperidina como inhibidores de CETP
JP5042311B2 (ja) * 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
PL2229356T3 (pl) 2007-12-03 2012-03-30 Novartis Ag 1,2-Dipodstawione pochodne 4-benzyloamino-pirolidyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
EP2229164A1 (de) * 2007-12-05 2010-09-22 Aarhus Universitet Erhöhung des plasma-hdl-cholesterinspiegels
GB0919431D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
SI3464336T1 (sl) 2016-06-01 2022-06-30 Athira Pharma, Inc. Spojine
CN114853670B (zh) * 2022-05-23 2023-11-21 沈阳药科大学 含有酰胺基团的喹啉类化合物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
US6140342A (en) 2000-10-31
EP0987251B1 (de) 2004-05-19
EP0987251A1 (de) 2000-03-22
CA2282183A1 (en) 2000-03-17
ES2220013T3 (es) 2004-12-01
DK0987251T3 (da) 2004-09-27
PT987251E (pt) 2004-10-29
BR9904141A (pt) 2000-09-12
JP3626641B2 (ja) 2005-03-09
US6362198B1 (en) 2002-03-26
CA2282183C (en) 2006-08-08
JP2000191645A (ja) 2000-07-11
DE69917400T2 (de) 2005-05-19
ATE267172T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
DE69917400D1 (de) 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer
BG105428A (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
CA2344248A1 (en) 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
BR9904162A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetra-hidroquinolinas aneladas
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
WO2004085401A8 (en) 1,2,4-substituted 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
WO1999047497A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
MX9704671A (es) Esteres y amidas de acidos carboxilicos antiinflamatorios no esteroidales que pueden usarse como antioxidantes, inhibidores de 5-lipoxigenasa y productos antiiflamatorios no esteroidales.
ATE230729T1 (de) Benzamid-derivate und ihre verwendung als vasopressin-antagonisten
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
AU6894800A (en) Caspase inhibitors and uses thereof
DK1642885T3 (da) Anvendelse af et farmaceutisk præparat der indeholder et para-aminophenyl-eddikesyrederivat til behandling af inflammatoriske tilstande i mave-tarmkanalen
ATE67503T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
WO2001057021A3 (en) 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
DK1256581T3 (da) Forebyggende eller terapeutiske midler til gastrisk eller ösofageal regurgitation
ES2090238T3 (es) Derivados benzhidriloxietilpiperidilos de acidos alifaticos y su aplicacion en el tratamiento del asma y de sus alergias.
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
EP1857444A1 (de) Tetrahydroisochinolinverbindung und deren medizinische verwendung
AU2068895A (en) Dl- di- or tri-hydroxyphenylglycine alkyl esters for the treatment of inflammatory and allergic conditions
DE60013515D1 (de) 4-Arylpiperidinderivate zur Behandlung von Pruritus
US6001851A (en) HIV protease inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee